PUBLIC COMPANY
saveUniversity of California San Francisco
updated 2mo ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
47
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Preclinical1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- FDA panel confronting peptide controversyToday's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."stat · 19d ago
- Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast CancerCapivasertib plus fulvestrant generated a numerical OS benefit vs placebo plus fulvestrant in PIK3CA/AKT1/PTEN-altered advanced breast cancer.onclive · 3mo ago
- STAT+: Katherine Szarama named acting director of FDA’s vaccines and biologics centerKatherine Szarama, who joined the FDA last year to serve as Vinay Prasad’s deputy, will now fill his shoes at CBER.stat · 3mo ago
comments(0)
5-min edit window · permanent after that